SPWM
LXRX icon

Straight Path Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Straight Path Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Hold
62,666
– – 0.04% 139
2026
Q1 		$97.8K Hold
62,666
– – 0.03% 128
2025
Q4 		$72.1K Hold
62,666
– – 0.02% 128
2025
Q3 		$84.6K Hold
62,666
– – 0.02% 140
2025
Q2 		$59.3K Hold
62,666
– – 0.02% 117
2025
Q1 		$28.9K Buy
+62,666
New +$39.5K 0.01% 109

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Straight Path Wealth Management's LXRX Position: Q2 2026 in Review

Straight Path Wealth Management held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 62,666 shares worth $150K. The position accounts for 0.04% of the portfolio, ranked #139.

Straight Path Wealth Management first reported a position in LXRX in Q1 2025 and has held it in 6 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Straight Path Wealth Management held 62,666 shares of Lexicon Pharmaceuticals worth $150K as of Q2 2026.
  • Straight Path Wealth Management left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up 0.04% of Straight Path Wealth Management's portfolio in Q2 2026, its #139 holding.
  • Straight Path Wealth Management first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Straight Path Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.